NA-Semax

NA-Semax Product Overview NA-Semax, also known as N-Acetyl Semax, is a chemically modified analogue of Semax. It retains the seven-residue Semax backbone while incorporating an acetyl group at the N-terminal methionine. The Semax backbone combines the ACTH(4–7)-derived sequence Met-Glu-His-Phe with the C-terminal tripeptide Pro-Gly-Pro. N-terminal acetylation creates a chemically distinct research material that should not be treated as interchangeable with standard Semax. Nuforme supplies NA-Semax as 10mg of lyophilized research material in a single vial. It is intended for controlled laboratory studies involving peptide stability, neurological signalling models and comparative analysis of Semax-related compounds. Product Specifications Product name: NA-Semax Declared identity: N-Acetyl Semax Peptide class: Modified synthetic heptapeptide Reference backbone sequence: Met-Glu-His-Phe-Pro-Gly-Pro Sequence abbreviation: MEHFPGP Declared N-terminal modification: Acetylation Quantity: 10mg Format: Lyophilized material Container: Single vial Relationship to Standard Semax Standard Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro and is commonly described as an ACTH-derived synthetic peptide. It contains an ACTH(4–7)-related tetrapeptide followed by Pro-Gly-Pro. NA-Semax adds an acetyl group to the N-terminal methionine. This modification can influence terminal charge, interaction with aminopeptidases, chromatographic behaviour, solubility and peptide stability. N-terminal acetylation should not automatically be described as producing greater potency, improved bioavailability or a longer duration of activity. These properties must be demonstrated in appropriate comparative experiments. The structural relationship to ACTH does not mean that NA-Semax is equivalent to intact ACTH or that findings concerning ACTH can be applied to this material. N-Acetyl Semax and N-Acetyl Semax Amidate N-Acetyl Semax and N-Acetyl Semax Amidate are separate chemical structures. N-Acetyl Semax free acid is generally represented as: Ac-Met-Glu-His-Phe-Pro-Gly-Pro-OH Formula: C39H53N9O11S Approximate molecular weight: 856.0 g/mol N-Acetyl Semax Amidate is represented as: Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2 Formula: C39H54N10O10S Approximate molecular weight: 855.0 g/mol The terms are sometimes used inconsistently in commercial catalogues. Researchers should verify the C-terminal structure, molecular formula and expected mass shown in the documentation for the individual batch. Research Background Most peer-reviewed research concerns standard Semax rather than N-Acetyl Semax specifically. Published experiments have examined standard Semax in cellular and animal models involving gene expression, neurotrophin-associated pathways, neurotransmitter systems, oxidative stress and responses to experimental neural injury. These findings provide background for designing comparative research but do not establish that NA-Semax produces identical, stronger or longer-lasting effects. The direct molecular targets of Semax-related peptides remain incompletely defined. Changes observed in BDNF, NGF, TrkB, monoamine or inflammatory-marker experiments should be described as model-dependent findings rather than a confirmed universal mechanism. Potential Research Areas Comparison of Semax and N-Acetyl Semax N-terminal acetylation and peptide-stability studies Aminopeptidase-resistance experiments Proteolytic degradation analysis Neurotrophin-associated gene-expression models Transcriptomic and proteomic studies Neuronal cell-signalling experiments Oxidative-stress and inflammatory-signalling models Melanocortin-related signalling hypotheses Concentration-response studies Target-identification and receptor-validation assays Analytical identity, purity and peptide-content testing Evidence Limitations Research findings for standard Semax should not automatically be transferred to NA-Semax. N-terminal acetylation changes the chemical structure and may alter interactions with enzymes, metals, membranes and biological targets. Direct comparative evidence for N-Acetyl Semax remains limited. Claims of improved cognitive performance, greater potency, enhanced absorption or extended activity should not be presented as established properties without compound-specific experimental data. Results obtained in animal, cellular or gene-expression models do not establish safety or effectiveness in humans. Analytical Considerations The batch documentation should identify the complete sequence, N-terminal modification, C-terminal form, expected molecular formula and theoretical mass. The difference between N-Acetyl Semax free acid and N-Acetyl Semax Amidate is approximately one dalton. Analytical methods require sufficient resolution to distinguish these structures reliably. Mass spectrometry may be used to evaluate molecular identity, while HPLC or UPLC can assess chromatographic purity. HPLC purity alone does not confirm the peptide sequence, acetylation site or C-terminal structure. Researchers should also consider methionine oxidation, deacetylated material, deletion sequences and other synthesis-related impurities. Quantitative peptide-content testing is required to confirm the amount of material present in the vial. Storage and Handling Store the unopened vial according to the product label and applicable batch documentation. Keep the material sealed and protected from inappropriate heat, light and moisture. Preparation, solution stability, working concentration and experimental storage conditions should be established through validated laboratory procedures. For laboratory research only. Not for human consumption, administration or veterinary use. This product is not a drug, medication, supplement or cosmetic and is not intended to diagnose, treat, cure or prevent any disease.

Pairs well with